IP Library Granted Patent US 12,110,345
Granted Patent B2
US 12,110,345 · App. 18/231,483 · Granted Oct 8, 2024

Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH

Inventor: Scott M. Duncan (Bedford, MA)
Assignee: Stealth BioTherapeutics Inc.
C07K5/1019C30B29/58C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,110,345
App. No.
18/231,483
Granted
Oct 8, 2024
Kind
B2
Abstract

Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH 2 .

Claims (25)

1. A crystalline form of the freebase of Compound (I),

(Boc)-D-Arg-DMT-Lys(Boc)-Phe-NH 2 ).

2. The crystalline form of claim 1 , wherein said crystalline form is characterized by an endothermic event in its thermogravimetry differential thermal analysis at an onset of about 168.5° C.

3. The crystalline form of claim 1 , wherein said crystalline form is characterized by an endothermic event in its thermogravimetry differential thermal analysis at a peak at about 175.9° C.

4. A method of preparing a crystalline form of the freebase of Compound (I), the method comprising:

a) preparing a mixture comprising the freebase of Compound (I) and a solvent; and

b) crystallizing the freebase of Compound (I) from the mixture.

5. The method of claim 4 , wherein the solvent is selected from methanol, ethanol, or trifluoroethanol.

6. The method of claim 5 , wherein the solvent is methanol.

7. The method of claim 4 , wherein the mixture is a solution, and the step of crystallizing the freebase of Compound (I) from the mixture comprises adding an anti-solvent, thereby causing the freebase of Compound (I) to precipitate.

8. The method of claim 7 , wherein the ratio of the solvent to the anti-solvent in the solution is about 3:1 to about 1:3 v/v.

9. The method of claim 7 , wherein the ratio of the solvent to the anti-solvent in the solution is about 3:1 v/v.

10. The method of claim 7 , wherein the ratio of the solvent to the anti-solvent in the solution is about 1:3 v/v.

11. The method of claim 7 , wherein the antisolvent is added at about 5 to about 50° C.

12. The method of claim 7 , wherein the antisolvent is added at about 50° C.

13. The method of claim 7 , wherein the antisolvent is added at about 5° C.

14. The method of claim 7 , wherein the anti-solvent is selected from acetonitrile, ethyl acetate, tetrahydrofuran, acetone, methyl ethyl ketone, toluene, tert-butyl methyl ether, and heptane.

15. A method of making Compound (II), the method comprising

(a) preparing a mixture of a crystalline form of the freebase of compound (I), a scavenger, and a solvent

(b) adding an acid to the mixture, thereby making compound (II)

16. The method of claim 15 , wherein

the scavenger is triisopropylsilane, the solvent is 2,2,2-trifluoroethanol and

the acid is hydrochloric acid.

17. The method of claim 16 , wherein the mixture is a slurry.

18. The method of claim 17 , further comprising isolating compound (II) from the mixture.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2023
From: STEALTH BIOTHERAPEUTICS CORP.
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 065105/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2023
From: DUNCAN, SCOTT M.
To: STEALTH BIOTHERAPEUTICS CORP.
Reel/Frame 065105/0456 →
Continuity (4)
Continuation 17225565 · Apr 8, 2021
Division 16603117
Provisional Application 62481766 · Apr 5, 2017
Related Publication 20240140990A1 · May 2, 2024